Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIb randomized double-blind placebo-controlled safety and efficacy study of BI 10773 in type 2 diabetes mellitus
2009-013668-38Phase 2Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Sep 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing BI 10773 with Placebo (2 arms). Primary endpoint: Change from baseline in HbA1c at 18 weeks. Started Sep 2009; status: completed.
02
Drugs
empagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2009-013668-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-013668-38.